Your Health, We Care
The most common adverse reactions (≥ 20%) are edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, and decreased appetite.
from FDA,2023.03
Capmatinib may make your skin more sensitive to sunlight, sunlamps, and tanning ···【more】
Release date：2026-01-09Recommended：27
Common side effects include fluid retention, nausea, vomiting, myalgia, fatigue,···【more】
Release date：2026-01-09Recommended：29
Capmatinib has shown significant efficacy in the treatment of non-small cell lun···【more】
Release date：2024-11-11Recommended：297
Capmatinib is a selective c-Met kinase inhibitor with significant anti-tumor act···【more】
Release date：2024-08-08Recommended：251
Capmatinib is a MET inhibitor developed by Novartis specifically for patients wi···【more】
Release date：2024-08-08Recommended：202
Capmatinib is an oral kinase inhibitor targeting mutations in the MET gene, prim···【more】
Release date：2024-08-08Recommended：219
